127 related articles for article (PubMed ID: 8404928)
21. [Lomefloxacin hydrochloride (Maxaquin), a long-acting fluoroquinolone (information for specialists)].
Kuznetsovoĭ SM
Antibiot Khimioter; 1998; 43(2):40-1. PubMed ID: 9551172
[No Abstract] [Full Text] [Related]
22. The in-vitro activity of two new quinolones: rufloxacin and MF 961.
Wise R; Andrews JM; Matthews R; Wolstenholme M
J Antimicrob Chemother; 1992 Jun; 29(6):649-60. PubMed ID: 1324239
[TBL] [Abstract][Full Text] [Related]
23. A multinational European survey on the in-vitro activity of rufloxacin and other comparative antibiotics on respiratory and urinary bacterial pathogens.
Schito GC; Acar JF; Bauernfeind A; Duval J; Finch RG; Focht J; Nicoletti G; Phillips I; Pratts G; Soriano F; Wiedeman B; Wise R
J Antimicrob Chemother; 1996 Oct; 38(4):627-39. PubMed ID: 8937958
[TBL] [Abstract][Full Text] [Related]
24. Susceptibility of Salmonella typhi and Brucella melitensis to the new fluoroquinolone rufloxacin (MF 934).
Qadri SM; Ayub A; Ueno Y; Saldin H
Chemotherapy; 1993; 39(5):311-4. PubMed ID: 8396527
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers.
Aguilar L; Balcabao IP; Salvá P; Martín M; Costa J; Prieto J; Dal-ré R
Antimicrob Agents Chemother; 1996 Jan; 40(1):17-21. PubMed ID: 8787872
[TBL] [Abstract][Full Text] [Related]
26. Microbiological studies on lomefloxacin--a new quinolone.
Newsom SW; Rowland C
J Chemother; 1989 Jul; 1(4 Suppl):168-9. PubMed ID: 16312354
[No Abstract] [Full Text] [Related]
27. Activities of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae.
Dalhoff A
Drugs; 1995; 49 Suppl 2():194-6. PubMed ID: 8549301
[No Abstract] [Full Text] [Related]
28. [The difluoroquinolone lomefloxacin--an broad spectrum antimicrobial drug].
Padeĭskaia EN; Iakovlev VP
Antibiot Khimioter; 1998; 43(2):30-9. PubMed ID: 9551171
[No Abstract] [Full Text] [Related]
29. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of temafloxacin against gram-negative bacteria: an overview.
Hardy DJ
Am J Med; 1991 Dec; 91(6A):19S-23S. PubMed ID: 1662890
[TBL] [Abstract][Full Text] [Related]
31. [The use of Maxaquin (lomefloxacin hydrochloride) in the treatment of nonspecific inflammatory diseases and in the prevention of surgical interventions in urology].
Derevianko II; Lopatkin NA; Khodyreva LA; Kondrat'eva EM
Urol Nefrol (Mosk); 1998; (5):14-8. PubMed ID: 9820038
[No Abstract] [Full Text] [Related]
32. Impact of rufloxacin and ciprofloxacin on the intestinal microflora in a germ-free mice model.
Gismondo MR; Drago L; Lombardi A; Fassina C; Cesana M
Chemotherapy; 1995; 41(4):281-8. PubMed ID: 7555209
[TBL] [Abstract][Full Text] [Related]
33. NM441: penetration into gynaecological tissues and in vitro activity against clinical isolates from obstetric and gynaecological patients.
Mikamo H; Kawazoe K; Izumi K; Ito K; Tamaya T
Drugs; 1995; 49 Suppl 2():326-30. PubMed ID: 8549350
[No Abstract] [Full Text] [Related]
34. Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections.
Mazzei T; Cassetta MI; Fallani S; Arrigucci S; Novelli A
Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S35-41. PubMed ID: 16829051
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial activity, pharmacokinetics and clinical studies of balofloxacin (Q-35) in obstetrics and gynaecology.
Cho N; Miyakawa Z; Kimura T; Shimizu A; Notake Y; Kunii K
Drugs; 1995; 49 Suppl 2():391-2. PubMed ID: 8549373
[No Abstract] [Full Text] [Related]
36. Concentration of enrofloxacin in equine tissues after long-term oral administration.
Giguère S; Bélanger M
J Vet Pharmacol Ther; 1997 Oct; 20(5):402-4. PubMed ID: 9350262
[No Abstract] [Full Text] [Related]
37. Comparison of the mechanism of action and resistance of two new fluoroquinolones, rufloxacin and MF961 with those of ofloxacin and fleroxacin in gram-negative and gram-positive bacteria.
Piddock LJ; Panchal S; Norte V
J Antimicrob Chemother; 1993 Jun; 31(6):855-63. PubMed ID: 8395493
[TBL] [Abstract][Full Text] [Related]
38. Quinolinecarboxylic acids. 3. Synthesis and antibacterial evaluation of 2-substituted-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de] [1,4]benzothiazine-6-carboxylic acids related to rufloxacin.
Cecchetti V; Fravolini A; Pagella PG; Savino A; Tabarrini O
J Med Chem; 1993 Oct; 36(22):3449-54. PubMed ID: 8230136
[TBL] [Abstract][Full Text] [Related]
39. [Grepafloxacin (Raxar)].
Friis HM
Ugeskr Laeger; 1998 Jul; 160(30):4438-41. PubMed ID: 9691842
[No Abstract] [Full Text] [Related]
40. [New quinolones].
Kakeya H; Fukushima K; Saito A
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():542-8. PubMed ID: 17455678
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
